ArticleAmerican journal of hematology2018
Genomic and clinical characterization of B/T mixed phenotype acute leukemia reveals recurrent features and T-ALL like mutations.
Article in American journal of hematology, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 25 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
25 citing papers in PubMed, 61 citations in OpenAlex.
- Significance of Myelodysplasia-Related Mutations and the Genetic Landscape of Acute Leukemias of Ambiguous Lineage.International journal of laboratory hematology · 2026Review
- Mixed-phenotype acute leukemia with trilineage differentiation presenting as a non-leukemic mediastinal tumor.Journal of clinical and experimental hematopathology : JCEH · 2025Article
- Pediatric T-Lymphoblastic Leukemia With Aberrant B-Cell Marker Expression: A Potential Role for Targeted Therapy.EJHaem · 2025Article
- Review
- Philadelphia chromosome-positive mixed-phenotype acute leukemia: a case report and literature review.Frontiers in oncology · 2025Review
- How to think about acute leukemia of ambiguous lineage.Hematology. American Society of Hematology. Education Program · 2024Review
- Article
- Measuring single-cell immune clonality to track haematological cancers.Clinical and translational medicine · 2024Article
- Genomic heterogeneity within B/T mixed phenotype acute leukemia in a context of an immunophenotype.Leukemia research reports · 2024Article
- Superior sagittal sinus thrombosis in the course of mixed phenotype acute leukaemia treated with acute lymphoblastic leukaemia-like therapy-a case report.Thrombosis journal · 2023Article
- Article
- Genomic Landscape of Mixed-Phenotype Acute Leukemia.International journal of molecular sciences · 2022Article
- Review
- MEF2C opposes Notch in lymphoid lineage decision and drives leukemia in the thymus.JCI insight · 2022Article
- Article
- B/T mixed phenotype acute leukemia with high hyperdiploidy and lineage switch to B-cell acute leukemia.Leukemia research reports · 2022Article
- BACH2-mediated FOS confers cytarabine resistance via stromal microenvironment alterations in pediatric ALL.Cancer science · 2021Observational
- A transcriptomic continuum of differentiation arrest identifies myeloid interface acute leukemias with poor prognosis.Leukemia · 2021Article
- Mixed Phenotype Acute Leukemia: Current Approaches to Diagnosis and Treatment.Current oncology reports · 2021Review
- TCRCell · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
16 authors at 6 institutions in 1 country.
Funding
Abstract
The B/T subtype of mixed phenotype acute leukemia (B/T MPAL) is defined by co-expression of antigens of both B- and T-cell lineages on leukemic blasts. Although it has been suggested that multilineage antigen expression portends poor response to chemotherapy, the clinical characteristics and driver mutations that underlie the pathogenesis of this rare subtype of acute leukemia are scarcely known. We identified nine cases of B/T MPAL from multiple institutions and correlated clinical and immunophenotypic findings with next-generation sequencing data. We report that B/T MPAL commonly presents with lymphadenopathy in adolescence and young adulthood. While the tumors have diverse cytogenetic and genomic perturbations, recurrent acquired aberrations include mutations in the putative transcriptional regulator PHF6 and the JAK-STAT and Ras signaling pathways. Alterations were also identified in genes encoding hematopoietic transcription factors, cell cycle regulators/tumor suppressors, and chromatin modifying enzymes. The genomic landscape of B/T MPAL strongly resembles that of T-ALL subgroups associated with early developmental arrest, while genetic alterations that are common in B-ALL were rarely seen. Two-thirds of the patients responded to ALL-based chemotherapy with or without stem cell transplantation. Our observations lay the groundwork for further study of the unique biology and clinical trajectory of B/T MPAL.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.